Patients with history of metabolic syndrome have increased risk for cardio-kidney-metabolic diseases and multimorbidity.

Metformin is a widely used first-line therapy for type 2 diabetes, and studies increasingly point to its protective effects ...

This study for the first time to integrate spatial metabolomics and proteomics to decode metformin’s effects in diabetic kidney disease. By mapping ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. AstraZeneca PLC stands fifth on our list among the most ...

From sarcopenia to ALS, researchers are exploring creatine’s broader clinical potential — but more trials are needed to confirm its value.

This clinical brief will explore the prevalence, clinical and economic burden, and management of cardiovascular-renal-metabolic (CRM) conditions while also identifying key areas of unmet need.

MPC inhibition reprograms mitochondrial metabolism, reducing insulin resistance in cells and driving metabolic benefits in organs throughout the body.

11060Background: Metabolic syndrome (MetS) is a known risk factor for developing at least 13 cancer types and adverse outcomes. However, the effects of MetS on their differential and cumulative impact ...

Researchers have found in a long-term study involving 1,894 patients over 9.2 years that higher levels of urinary choline and dimethylglycine are associated with increased risks of renal events and ...

Here, we summarize the evidence available to date and propose a more general involvement of metabolic and mitochondrial alterations in the renal ciliopathies that might in principle help defining the ...

Cardiac, renal, and metabolic (CRM) conditions are major causes of morbidity and mortality globally. This study aims to explore the relationship between serum uric acid (SUA), hyperuricemia, gout, and ...